Prosensa re-starts drisapersen dosing amid analyst skepticism
This article was originally published in Scrip
Prosensa has restarted dosing patients with drisapersen, its Duchenne muscular dystrophy (DMD) drug candidate, which had been suspended following the failure of the Phase III DEMAND study last year, which led to GlaxoSmithKline returning rights to the drug in January. However, analysts remain skeptical of the Dutch biotech's chances of success.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.